Leukemia can arise at various stages of the hematopoietic differentiation hierarchy, but the
impact of developmental arrest on drug sensitivity is unclear. Applying network-based …

Purpose: Systems biology approaches can identify critical targets in complex cancer
signaling networks to inform new therapy combinations that may overcome conventional …

T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive hematological malignancy and
new therapeutics are much needed. Profiling patient leukemia drug sensitivities ex vivo, we …

Contemporary chemotherapy for childhood acute lymphoblastic leukemia (ALL) is risk-
adapted based on clinical features, leukemia genomics and minimal residual disease …

Acute lymphoblastic leukemia (ALL) is the most common malignancy of childhood and is
treated with chemotherapy alone or, in particular subgroups, with additional radiation …

Highlights•B-cell precursor acute lymphoblastic leukemia (BCP-ALL) is currently treated by
risk-adapted intensive chemotherapy•Genome-wide genomic analyses have uncovered the …

Childhood acute lymphoblastic leukemia (ALL) genomes show that relapses often arise from
subclonal outgrowths. However, the impact of clonal evolution on the actionable proteome …

Acute myeloid leukemia (AML) is a cancer of myeloid-lineage cells with limited therapeutic
options. We previously combined ex vivo drug sensitivity with genomic, transcriptomic, and …

Despite the expanding portfolio of targeted therapies for adults with acute myeloid leukemia
(AML), direct implementation in children is challenging due to inherent differences in …

Drug resistance and treatment failure in pediatric acute lymphoblastic leukemia (ALL) are in
part driven by tumor heterogeneity and clonal evolution. Although bulk tumor genomic …